Garadacimab
BLOOD AND BLOOD FORMING ORGANS
Also known as: andembry, CSL312, garadacimab-gxii
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Garadacimab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2025. DrugCentral lists 1 molecular target, including F12. Recorded indications include Hereditary angioneurotic edema.
- Molecular targets: F12 (1 listed in DrugCentral).
- Indications: Hereditary angioneurotic edema.
- ATC code: B06AC07 (Drugs used in hereditary angioedema).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hereditary angioneurotic edema
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Coagulation factor XII | F12 | inhibitor | Kd 7.26 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2025-06-16 | FDA | — | CSL Behring | Yes |
| 2025-02-20 | PMDA | — | CSL Behring K.K. | Yes |
| 2025-02-10 | EMA | — | CSL Behring GmbH | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B06AC07 | BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Hereditary angioedema | 112.3 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Garadacimab used for?
DrugCentral lists the following indications for Garadacimab: Hereditary angioneurotic edema.
How does Garadacimab work?
Its molecular targets in DrugCentral include F12 (inhibitor).
When was Garadacimab first approved?
Garadacimab was first approved by the EMA in 2025.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5776 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- DrugBank DB15629 — drug record
- FDA UNII 32W6AJL0DY — substance identity
- DailyMed: FDA labels for Garadacimab — current prescribing information (label search)
- UniProt P00748 (F12) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.